Decision analytic modeling for primary open-angle glaucoma (POAG) has been undertaken for more than 35 years in 15 different countries, providing enough background and useful insights to guide future modeling research.

Existing economic assessments include the study of topical medications, screening or diagnosis alternatives, surgery, laser trabeculoplasty and minimally invasive surgeries.

The structure of a decision analytic model for POAG can be justified by using published glaucoma staging systems from a clinical standpoint.

Evidence gaps in the literature are associated with a lack of competing alternatives, inclusion of treatment sequences and sufficient justification of key modeling assumptions, inputs and outcomes robustness.